Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization. Issue 6 (1st June 2022)

• Record Type: Journal Article
• Authors: Liu, Yuwei; Long, Kaiqi; Kang, Weirong; Wang, Tianyi; Wang, Weiping
• Is Part Of: Advanced nanobiomed research. Volume 2:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-01
• Subjects: Nanomedicine -- Periodicals; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; Nanomedicine; Nanostructures; Bioengineering; Biocompatible Materials; Electronic journals; Periodicals; Periodical; 610.28
• DOI: 10.1002/anbr.202270061
• Languages: English
• ISSNs: 2699-9307

Abstract

Abstract : Immunotherapy In article number 2200017, Weiping Wang and co‐workers report a photoactivatable and biocompatible prodrug. The prodrug is not able to block PD‐1 (expressed on T cells (yellow)) and PD‐L1 (expressed on cancer cells (blue)) interaction. Upon 420 nm light irradiation, the prodrug can exert effective PD‐1/PD‐L1 axis inhibition by inducing PD‐L1 dimerization. The prodrug can recover the immune functions of T cells with negligible cytotoxicity.